Corcept Therapeutic Soars, Abbott Labs Sinks, Arista Networks Jumps on AI Spending

On this episode of Stock Movers:
- Corcept Therapeutic (CORT) shares soar after the pharmaceutical firm said its Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer met its overall survival primary endpoint, showing a 35% reduction in death risk compared to nab-paclitaxel alone.
- Abbott Labs (ABT) shares sink after the medical devices firm forecasted first-quarter earnings that fell short of estimates. The company also reported organic sales for the fourth quarter that missed Wall Street’s estimates.
- Arista Networks (ANET) shares jump. The company has been a beneficiary of AI-related spending, rising more than 370% since the end of 2022. Piper Sandler upgraded the stock earlier this month.

See omnystudio.com/listener for privacy information.